Abstract
Non-obstructive azoospermia (NOA) is the most severe form of male infertility and typically incurable with current medicine. Due to the biological complexity of sperm production, defining the genetic basis of NOA has proven challenging, and to date, the most advanced classification of NOA subforms is based on simple description of testis histology. In this study, we exome-sequenced over 1,000 clinically diagnosed NOA cases and identified a plausible recessive Mendelian cause in 20%. Population-based testing against fertile controls identified 27 genes as significantly associated with azoospermia. The disrupted genes are primarily on the autosomes, enriched for undescribed human “knockouts”, and, for the most part, have yet to be linked to a Mendelian trait. Integration with single-cell RNA sequencing of adult testes shows that, rather than affecting a single cell type or pathway, azoospermia genes can be grouped into molecular subforms with highly synchronized expression patterns, and analogs of these subforms exist in mice. This analysis framework identifies groups of genes with known roles in spermatogenesis but also reveals unrecognized subforms, such as a set of genes expressed specifically in mitotic divisions of type B spermatogonia. Our findings highlight NOA as an understudied Mendelian disorder and provide a conceptual structure for organizing the complex genetics of male infertility, which may serve as a basis for disease classification more advanced than histology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Institutes of Health of the United States of America grant R01HD078641 (D.F.C, K.I.A) National Institutes of Health of the United States of America grant P50HD096723 (D.F.C.) National Health and Medical Research Council of Australia grant APP1120356 (M.O., D.C., K.I.A., R.M. and J.A.V.) Spanish Ministry of Health Instituto Carlos III-FIS grant FIS/FEDER-PI20/01562 (CK, A.R.-E.). Estonian Research Council grants IUT34-12 and PRG1021 (M.L., M.P.) ReproUnion and the Innovation Fund Denmark grant 14-2013-4 (K.A.) German Research Foundation Clinical Research Unit 'Male Germ Cells' grant DFG CRU326 (C.F., F.T.) The Netherlands Organization for Scientific Research VICI grant 918-15-667 (J.A.V.) Investigator Award in Science from the Wellcome Trust grant 209451 (J.A.V.). FCT/MCTES, through national funds attributed to Centre for Toxicogenomics and Human Health-ToxOmics, grant UID/BIM/00009/2016 (J.G.) National Institute of Mental Health of the National Institutes of Health grant T32-MH014677 (W.-L.C)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of all collaborative centers: protocols #201107177 and #201109261 approved by the institutional review board (IRB) of Washington University in St. Louis, USA; IRB_00063950 approved by IRB of University of Utah, USA; PTDC/SAU-GMG/101229/2008 approved by the Ethics Committee and Hospital Authority, University of Porto, Portugal; 16030459 and 0102004794 approved by the IRB of Weill Cornell Medical College, New York, USA; Ref. No.: 2014/04c approved by the IRB of Fundacio Puigvert, Barcelona, Spain; NL50495.091.14 version 4 approved by the Research Ethics Committee of the Radboud University, Nijmegen, The Netherlands; Ref: 18/NE/0089, Bursa: 05.01.2015/04 approved by the University Research Ethics Committee of University of Newcastle, UK; and ethical approvals from human ethics committees of Monash Surgical Day Hospital, Monash Medical Centre and Monash University, Australia; the ethics committee for the Capital Copenhagen Region (Ref. Nr. H-2-2014-103) and the Danish Personal Data Protection Agency (Datatilsynet 2012-58-0004, local Nr. 30-1482, I-Suite 03696) gave ethical approval for this work in accordance to the European Commission Directive for the transfer of personal data (MTA/I-4728.A1); the Ethics Committee of National Institute of Health Dr Ricardo Jorge, Lisboa, Portugal gave ethical approval for this work; and approval 74/54 (last amendment 288/M-13) released by Research Ethics Committee of the University of Tartu, Estonia. The MERGE study protocol was given ethical approval by the Ethics Committee of the Arztekammer Westfalen-Lippe and the University of Munster (Ref. No. 2010-578-f-S). Written informed consent was obtained from all men.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sequencing data that support the findings of this study are either in process of being deposited in dbGAP database and the accession numbers will be available by the time of publication.
